10-QHealthcare

Nurix Therapeutics, Inc.

NRIX · Period ending 2026-08-31 · Filed 2026-10-13 · Updated

In short

Nurix Therapeutics, Inc. (NRIX) has revenue up 54.0% to $84.0M and net income down 36.6% to -$264.5M year on year. Fisclear flags 2 high-severity risks, led by: Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$12.85

P/E (TTM)

5.3x

Price ÷ earnings per share

P/B

1.4x

Price ÷ book value

P/S (TTM)

2.0x

Price ÷ revenue per share

Beta

1.78

High volatility vs market

52-Week Range

$12.83$12.85 now$28.23

Decision Context

Below-average scores in Efficiency, Cashflow. The data points to fundamental challenges that outweigh near-term macro considerations.

Based on filing period ending Aug 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

NRIX vs

Macro Context

Fed Funds Rate

3.75%

Accommodative

10-Year Treasury

4.99%

2026-09-01

Unemployment

4.2%

Near full employment

CPI Index

334.1

2026-08-01

M2 Money Supply

$23.3T

2026-08-01

The Federal Funds rate stands at 3.75% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.99%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 103.1; M2 money supply is $23.3T; CPI index stands at 334.1.

SWOT Analysis — NRIX

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Revenue: $84.0M (+54.0% YoY) — Revenue grew 54% — the company sold more goods or services than the prior year.

◈

Weaknesses

  • Operating Cash Flow: -$249.5M (-44.5% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.

  • Net Income: -$264.5M (-36.6% YoY) — The company posted a net loss — total expenses exceeded total revenue.

  • EPS (Diluted): $-3.05 (-5.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.

  • R&D spending is 377% of revenue — heavy investment in future growth, but also a drag on current profitability.

  • Beta of 1.82x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.

◎

Opportunities

  • Total Assets: $688.1M (+2.8% YoY) — Total assets grew 3% — the company's resource base expanded.

⚠

Threats

  • Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.

  • Negative operating cash flow of $249.5M — the core business consumed more cash than it generated.

Year-over-Year Changes

Revenue

$84.0M

was $54.5M

+54.0%

Revenue grew 54% — the company sold more goods or services than the prior year.

Operating Cash Flow

-$249.5M

was -$172.6M

−44.5%

Negative operating cash flow — the business consumed more cash than it produced from operations.

Net Income

-$264.5M

was -$193.6M

−36.6%

The company posted a net loss — total expenses exceeded total revenue.

EPS (Diluted)

$-3.05

was $-2.88

−5.9%

Negative EPS — the company recorded a loss on a per-share basis.

Total Assets

$688.1M

was $669.3M

+2.8%

Total assets grew 3% — the company's resource base expanded.

Risk Flags

2 high · 0 medium · 2 low
  • ⚠ High

    Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.

  • ⚠ High

    Negative operating cash flow of $249.5M — the core business consumed more cash than it generated.

  • ○ Low

    R&D spending is 377% of revenue — heavy investment in future growth, but also a drag on current profitability.

  • ○ Low

    Beta of 1.82x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.

Technical Signals

Daily closes · 1-year data

Nurix Therapeutics, Inc.: common questions

Is Nurix Therapeutics, Inc. profitable?

No. Nurix Therapeutics, Inc. reported a net loss of $264M in its latest fiscal year (fiscal 2025).

Is Nurix Therapeutics, Inc.'s revenue growing?

Yes. Revenue grew 54.0% year on year, to $84.0M.

What is Nurix Therapeutics, Inc.'s P/E ratio?

Nurix Therapeutics, Inc. trades at 5.3× its trailing twelve-month earnings. In other words, the share price is about 5 times the profit per share the company earned over the past year.

Does Nurix Therapeutics, Inc. pay a dividend?

No dividend is currently expected from Nurix Therapeutics, Inc., according to the latest market data.

What are the main risks for Nurix Therapeutics, Inc.?

Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.

Answers are generated from the figures in this report (updated 13 Oct 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — NRIX

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade NRIX

Links open broker research pages. Not an endorsement or recommendation.

Research Nurix Therapeutics, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.